Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AGNC Investment Corp (AGNC) vs Quest Diagnostics Inc (DGX) Price & Performance

AGNC Investment Corp
Quest Diagnostics Inc

Price performance

Price movement over the last 24 hours

Key statistics

AGNC Investment Corp vs Quest Diagnostics Inc — how do they compare? AGNC Investment Corp trades at $10.96 (market cap $12.76B), while Quest Diagnostics Inc trades at $207.24 (market cap $23.51B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and AGNC Investment Corp pays the higher dividend (12.95%). Which is the better fit depends on your goals.

AGNCDGX
Market Cap
$12.76B$23.51B
Sector
FinancialsHealth
52-Week High
$12.17$216.02
52-Week Low
$9.20$166.42
Dividend Yield
12.95%1.62%
Enterprise Value
$29.52B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AGNC Investment Corp

AGNC trades at $11.12, up 1.09% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $11.33. The stock shows strong profitability with a net income margin of 91.71% and ROE of 13.98%, though recent earnings have been mixed with a Q1 2026 beat but misses in prior quarters. Dividend payments of $0.12 per share continue regularly, supporting income-focused investors amid interest rate sensitivity concerns highlighted in recent news.

Outlook remains cautiously optimistic given analyst buy ratings (37.14%) and technical momentum, but risks include Federal Reserve policy shifts impacting mortgage-backed securities and earnings volatility. The stock's valuation at P/E 8.73 and P/B 1.26 offers relative value, though investors must monitor interest rate trends for dividend sustainability and book value stability.

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $212.38, down 1.55% today but remains near its 52-week high. The stock shows strong fundamental performance with three consecutive quarterly earnings beats and revenue growth to $11.04 billion in 2025. Technical indicators suggest a bullish trend with support at $212 and resistance at $216. Recent positive developments include New York State approval for the Haystack MRD cancer test, expanding market reach.

DGX presents a balanced investment case with solid fundamentals and analyst support, though valuation appears full. The consensus price target of $222.80 offers modest upside. Key risks include healthcare reimbursement pressures and elevated debt levels. Earnings growth and diagnostic service expansion remain primary catalysts for continued performance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AGNC Investment Corp

AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage or real estate markets.

Read more on AGNC

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX